Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lonza Group Ltd ( (CH:LONN) ) just unveiled an update.
Lonza Group Ltd reported a strong performance in Q1 2025, aligning with its full-year expectations. The company confirmed its outlook for 2025, with significant growth anticipated in its CDMO and Capsules & Health Ingredients divisions. Lonza is progressing well with its growth projects, including new facilities in Visp and Stein, and is preparing for the exit of its CHI business. The company also completed a share buyback program, reflecting confidence in its strategic direction.
More about Lonza Group Ltd
Lonza is one of the world’s largest contract development and manufacturing organizations (CDMOs) dedicated to serving the healthcare industry. With a global team of around 18,500 colleagues, Lonza collaborates with pharma and biotech companies to transform innovative ideas into viable therapies, supporting the delivery of life-saving and life-enhancing treatments worldwide.
Average Trading Volume: 184,881
Current Market Cap: CHF41.67B
For a thorough assessment of LONN stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “They Read Like a Cry for Help”, Starbucks Stock (NASDAQ:SBUX) Notches Up Despite Cup Note Concerns
- “The Merger of Marketing and Tech has Never Been Greater”: Home Depot Stock (NYSE:HD) Swings Up With Growing Marketing Plans
- Why Arista Networks Stock (ANET) Is Down Today and Why Morgan Stanley Says ‘Take the Plunge’